Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
284 hedge funds and large institutions have $8.37B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2021 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 111 increasing their positions, 82 reducing their positions, and 32 closing their positions.
116% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 32
35% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 82
14% more funds holding
Funds holding: 249 → 284 (+35)
5% more capital invested
Capital invested by funds: $8B → $8.37B (+$376M)
6% less call options, than puts
Call options by funds: $131M | Put options by funds: $139M
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$86.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$81.5M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$44.4M |
| 4 |
EP
Eversept Partners
New York
|
+$40.1M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$39.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$213M |
| 2 |
CII
Capital International Inc
Los Angeles,
California
|
-$56.2M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$45.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$30.7M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$23.4M |
BHVN Hedge Fund Activity: Q4 2021 in Review
284 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2021, worth a combined $8.37B — up 4.7% from $8B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new BHVN positions and 32 closed out — a net gain of 37 holders — while 111 added to existing stakes and 82 trimmed.
The largest buyer was Thrivent Financial for Lutherans, opening a new position worth an estimated $86.7M. The largest seller was Wells Fargo, cutting an estimated $213M.
- 284 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2021, up from 249 in Q3 2021.
- Funds reported $8.37B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2021, up 4.7% quarter-over-quarter.
- 69 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2021 and 32 closed out, a net change of +37 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2021 was Thrivent Financial for Lutherans, an estimated $86.7M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q4 2021 was Wells Fargo, an estimated $213M sold.
Based on aggregated 13F filings for Q4 2021.